Further use of protein kinase N beta
The present invention is related to use of protein kinase N beta or a fragment or derivative thereof as a downstream target of the PI 3-kinase pathway, preferably as a downstream drug target of the PI 3-kinase pathway.
1. A pharmaceutical composition comprising at least one agent that inhibits the activity of protein kinase N beta and a pharmaceutically acceptable carrier, wherein said agent is an siRNA that inhibits the expression of protein kinase N beta, and wherein said siRNA:
is encoded by a nucleotide sequence comprising SEQ ID NO: 13 or SEQ ID NO: 14; or
comprises a sense and an antisense sequence joined by a poly A linker, the sense sequence being encoded by SEQ ID NO: 13 or SEQ ID NO: 14 and the antisense sequence by a reverse complementary sequence of SEQ ID NO: 13 or SEQ ID NO: 14.
2. The composition according to claim 1 , wherein said siRNA is encoded by a nucleotide sequence comprising SEQ ID NO: 13 or SEQ ID NO: 14.
3. The composition according to claim 1 , wherein said siRNA molecule comprises a sense and an antisense sequence joined by a poly A linker, the sense sequence being encoded by SEQ ID NO: 13 or SEQ ID NO: 14 and the antisense sequence by a reverse complementary sequence of SEQ ID NO: 13 or SEQ ID NO: 14.
4. The composition according to claim 3 , wherein said poly A linker is a 12-mer linker.
5. The composition according to claim 2 , wherein said siRNA is encoded by a nucleotide sequence comprising SEQ ID NO: 13.
6. The composition according to claim 2 , wherein said siRNA is encoded by a nucleotide sequence comprising SEQ ID NO: 14.
7. The composition according to claim 3 , wherein said siRNA molecule comprises a sense and an antisense sequence joined by a poly A linker, the sense sequence being encoded by SEQ ID NO: 13 and the antisense sequence by a reverse complementary sequence of SEQ ID NO: 13.
8. The composition according to claim 3 , wherein said siRNA molecule comprises a sense and an antisense sequence joined by a poly A linker, the sense sequence being encoded by SEQ ID NO: 14 and the antisense sequence by a reverse complementary sequence of SEQ ID NO: 14.